Efficacy and safety of applying rivaroxaban to prevent deep venous thrombosis in patients underwent hip arthroplasty

Objective To explore the efficiency and safety of applying rivaroxaban to prevent deep venous thrombosis in patients underwent hip arthroplasty. Methods One hundred and twenty cases of patients underwent hip arthroplasty were randomly divided into two groups, research group(60 cases treated with rivaroxaban) and control group(60 cases treated with LMWH). Color doppler examination was carried out to evaluate the formation of DVT in both lower limbs before and after the surgery and after the medication. The volume of drainage was also recorded. The hepatic and renal function, blood routine and urine routine were detected during the medication. Besides, bleeding of patients was observed and coagulation indicators were detected regularly. Results In LMWH group, there were 6 cases of DVT(10.00%), while in rivaroxaban group there were 5 cases of DVT(8.33%). There was no significant difference in the incidence of DVT between the two groups(P0.05). The postoperative volume of drainage in rivaroxaban group was(95.8±6.1) ml, while in LMWH group it was(94.5±6.5) ml. Moreover, there was no significant difference in the volume of drainage, APTT, PT and PLT between the two groups(P0.05). No adverse events, such as bleeding or pulmonary embolism, were found in both groups. Conclusion Rivaroxaban had the same efficacy and safety in the prevention of deep vein thrombosis in patients after total hip arthroplasty as low molecular weight heparin. Furthermore, it can avoid hematoma caused by subcutaneous injection of low molecular weight heparin and is easier to be used with better compliance.